Article info

Original research
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

Authors

  1. Correspondence to Dr Raj Tummala; Raj.Tummala{at}astrazeneca.com
View Full Text

Citation

Tummala R, Abreu G, Pineda L, et al
Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials

Publication history

  • Received November 25, 2020
  • Revision received January 11, 2021
  • Accepted January 11, 2021
  • First published February 17, 2021.
Online issue publication 
July 06, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.